智通财经APP讯，九源基因(02566)公布2026年中期业绩，收入约6.31亿元，同比减少1.23%;母公司股东应占净利润9126.9万元，同比增长1.21%;每股盈利0.38元。
公告称，上半年公司营收出现小幅下滑，主要受多方面因素共同作用：一是财政部、税务总局发布自2026年1月施行的10号新政将普通生物制品由3%简易征税调整为13%一般计税，公司整体实际税负率提升;二是受DRG/DIP支付方式改革深化等因素影响，医保“打包付费”模式倒逼医院控费，院端次均费用下降;三是公司主动加强资金和应收账款管控进一步压降票据规模、优化应收账款账期，部分订单让位于回款质量，营收端因此呈现主动降速、现金优先的略微下行。
报告期内，凭借公司优质的产品供应能力及成本优势，公司两款已集采产品吉欧停®、亿喏佳®顺利完成续约;此外，去年已上市产品吉新芬®、吉立欣®在报告期内销售数量均保持较快的增速。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.